APTO Aptose Biosciences Inc.: Company Short-Term Debts

Symbol and logo of brand Aptose Biosciences Inc (APTO)

The daily price chart for Aptose Biosciences Inc. (APTO) reflects the performance of a company developing high-cost treatments for hematologic malignancies under FDA supervision. The current metric stands at 0.00, yet the business faces a critical liquidity shortage that threatens the suspension of tuspetinib trials and potential delisting. Nevertheless, ownership of unique kinase inhibitor patents creates a closed ecosystem that binds medical centers to Aptose Biosciences Inc. (APTO) protocols.

APTO aptose.com Company Short-Term Loans and Borrowings (07/04/2022 - 04/13/2025)

Aptose Biosciences Inc - analytical breakdowns and key metrics (APTO)

- stock price and consensus target price:
Stock Price Aptose|APTO - Consensus Target
- company stock capitalization data:
Market Capitalization Aptose Biosciences Inc.|APTO - Total Enterprise Value
- business book valuation details:
Net Assets per Single Share Aptose Biosciences|APTO - Accounting Value of Company|Market Cap to Net Assets Ratio aptose.com|APTO - Aggregate Asset Value
- debt and liquidity details:
Total Debt to Capital Aptose Biosciences Inc.|APTO - Long-Term Debt to Equity|Short-Term Debt to Equity Aptose|APTO - Company Debts|Debt to Book Capitalization Ratio Aptose Biosciences Inc.|APTO - Long-Term Debt|Company Short-Term Debt Aptose Biosciences|Quick Ratio aptose.com
- earnings and multiples data:
APTO - Company Profit
Fundamental company valuation:APTO - aptose.com
Manufactured products of Aptose

The fabless model of Aptose Biosciences Inc. (APTO), which outsources drug synthesis to third-party contractors, minimizes capital expenditures by shifting the financial burden to operational obligations. This indicator aggregates all loans and borrowings with a maturity of up to one year, reflecting liquidity and debt management discipline, which allows the short-term debt chart to differentiate scheduled payments from a critical cash deficit.

Main competitors

TG Therapeutics - Company Short-Term Debts|Arcellx Inc (ACLX) - Company Current Liabilities|IRON: Company Short-Term Debts|Short-Term Debt Syndax Corp (SNDX)|Company Short-Term Debt Kura Oncology, Inc.|ADCT: Company Short-Term Loans and Borrowings|Company Current Liabilities FHTX (Foghorn Therapeutics)|VOR (Vor Biopharma, Inc.) - Company Short-Term Loans and Borrowings|Company Short-Term Debts NKTX (Nkarta)|Coeptis Therapeutics Inc. - Company Short-Term Debt|ATNM - Company Short-Term Debt|ESLA: Company Short-Term Debt|casipharmaceuticals.com (CASI) - Company Short-Term Debt|Short-Term Debt Marker Therapeutics, Inc. (MRKR)|Company Short-Term Debt IN8bio, Inc|Short-Term Debt Eterna Therapeutics Inc ERNA|Company Short-Term Debts GTBP|biopathholdings.com - Company Short-Term Indebtedness|Company Short-Term Debts MEIP (MEI Pharma)|Company Short-Term Debts Vincerx Pharma Inc. VINC